Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antineoplastic Combined Chemotherapy Protocols"" wg kryterium: Temat


Tytuł :
A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Autorzy :
Fountzilas C; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Adjei A; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Opyrchal M; Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Evans R; Clinical Research Services, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Ghasemi M; Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Attwood K; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Groman A; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Bshara W; Pathology Resource Network, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Goey A; Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Wilton J; Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Ma WW; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.
Iyer R; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Dec 15; Vol. 149 (12), pp. 2063-2074. Date of Electronic Publication: 2021 Aug 27.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Deoxycytidine/*analogs & derivatives
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Pyrimidines/*administration & dosage
Sulfones/*administration & dosage
Adult ; Aged ; Anaplastic Lymphoma Kinase/antagonists & inhibitors ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/pharmacokinetics ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Neoplasms/mortality ; Neoplasms/pathology ; Progression-Free Survival ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/pharmacokinetics ; Pyrimidines/adverse effects ; Pyrimidines/pharmacokinetics ; Sulfones/adverse effects ; Sulfones/pharmacokinetics
Czasopismo naukowe
Tytuł :
T cell ALL in a child with Ataxia telangiectasia; diagnosis and management challenges.
Autorzy :
Ahmed O; Pediatric Hematology Oncology department, Princess Nora Oncology center, King Abdul-Aziz Medical city, Jeddah, Saudi Arabia.
Felimban Y; Pediatric department, Maternity and Children Hospital, Dammam, Saudi Arabia.
Almehdar A; Radiology department, King Abdul-Aziz Medical city, Jeddah, Saudi Arabia.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 348-354.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Ataxia Telangiectasia/*complications
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*complications
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Brain/drug effects ; Brain/pathology ; Disease Management ; Humans ; Infant ; Male ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/genetics
Czasopismo naukowe
Tytuł :
Combined delivery of salinomycin and docetaxel by dual-targeting gelatinase nanoparticles effectively inhibits cervical cancer cells and cancer stem cells.
Autorzy :
Wang Q; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Yen YT; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Xie C; Key Laboratory for Organic Electronics and Information Displays, Institute of Advanced Materials (IAM), Jiangsu National Synergetic Innovation Center for Advanced Materials (SICAM), Nanjing University of Posts & Telecommunications, Nanjing, China.
Liu F; Department of pathology, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
Liu Q; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Wei J; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Yu L; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Wang L; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Meng F; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Li R; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Liu B; The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China.
Pokaż więcej
Źródło :
Drug delivery [Drug Deliv] 2021 Dec; Vol. 28 (1), pp. 510-519.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Drug Delivery Systems*
Nanoparticles*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Uterine Cervical Neoplasms/*drug therapy
Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Docetaxel/administration & dosage ; Drug Carriers/chemistry ; Female ; Gelatinases/metabolism ; HeLa Cells ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Neoplasm Transplantation ; Neoplastic Stem Cells/drug effects ; Polyesters/chemistry ; Polyethylene Glycols/chemistry ; Pyrans/administration & dosage ; Uterine Cervical Neoplasms/pathology
Czasopismo naukowe
Tytuł :
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Autorzy :
Lee Y; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.
Kim YS; Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Hong B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Cho YM; Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Lee JL; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Nov; Vol. 147 (11), pp. 3421-3429. Date of Electronic Publication: 2021 Mar 14.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Urinary Bladder Neoplasms/*drug therapy
Urologic Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cisplatin/administration & dosage ; Cisplatin/adverse effects ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Humans ; Male ; Methotrexate/administration & dosage ; Methotrexate/adverse effects ; Middle Aged ; Neoplasm Invasiveness ; Randomized Controlled Trials as Topic ; Retrospective Studies ; Survival Rate ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/surgery ; Urologic Neoplasms/pathology ; Urologic Neoplasms/surgery ; Vinblastine/administration & dosage ; Vinblastine/adverse effects
SCR Protocol :
M-VAC protocol
Czasopismo naukowe
Tytuł :
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
Autorzy :
Rutherford SC; Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA. Electronic address: .
Abramson JS; Department of Haematology and Oncology, Massachusetts General Hospital, Boston, MA, USA.
Bartlett NL; Washington University School of Medicine, Siteman Cancer Center, St Louis, MO, USA.
Barta SK; Division of Haematology and Oncology, University of Pennsylvania, Perelman Center for Advanced Medicine, Philadelphia, PA, USA.
Khan N; Fox Chase Cancer Center, Philadelphia, PA, USA.
Joyce R; Beth-Israel Deaconess Medical Center, Boston, MA, USA.
Maddocks K; James Cancer Hospital, Ohio State University, Columbus, OH, USA.
Ali-Shaw T; Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA.
Senese S; Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA.
Yuan Y; Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Westin J; Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leonard JP; Weill Cornell Medicine, Meyer Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Nov; Vol. 8 (11), pp. e818-e827. Date of Electronic Publication: 2021 Oct 08.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bridged Bicyclo Compounds, Heterocyclic/*therapeutic use
Lymphoma, B-Cell/*drug therapy
Sulfonamides/*therapeutic use
Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/therapeutic use ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Doxorubicin/therapeutic use ; Etoposide/administration & dosage ; Etoposide/adverse effects ; Etoposide/therapeutic use ; Female ; Humans ; Lymphoma, B-Cell/pathology ; Male ; Maximum Tolerated Dose ; Middle Aged ; Prednisone/administration & dosage ; Prednisone/adverse effects ; Prednisone/therapeutic use ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Treatment Outcome ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Vincristine/therapeutic use
SCR Protocol :
EPOCH protocol
Czasopismo naukowe
Tytuł :
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.
Autorzy :
Maguire WF; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Schmitz JC; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.
Scemama J; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.
Czambel K; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.
Lin Y; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center Biostatistics Facility, Pittsburgh, PA, USA.; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.
Green AG; Pitt Biospecimen Core Research Histology Department, Health Sciences Core Research Facilities, Pittsburgh, PA, USA.
Wu S; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; School of Pharmaceutical Science, Southern Medical University, Guangzhou, China.
Lin H; Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA.; Roche Product Development, Roche (China) Holding Ltd., Shanghai, China.
Puhalla S; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Rhee J; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Stoller R; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Tawbi H; Department of Melanoma and Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Lee JJ; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Wright JJ; Cancer Therapy Evaluation Program, National Cancer Institute, NIH, Bethesda, MD, USA.
Beumer JH; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Chu E; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA.; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Oncology and Cancer Therapeutics Program, Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Appleman LJ; Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. .; Cancer Therapeutics Program, UPMC Hillman Cancer Center, 5150 Centre Avenue, Pittsburgh, PA, USA. .; UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. .
Pokaż więcej
Corporate Authors :
ETCTN-9153 Study Team
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2021 Oct; Vol. 88 (4), pp. 643-654. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Neoplasms/*drug therapy
Proto-Oncogene Proteins c-met/*antagonists & inhibitors
Tubulin/*metabolism
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Bevacizumab/administration & dosage ; Dose-Response Relationship, Drug ; Female ; Humans ; Male ; Middle Aged ; Neoplasms/pathology ; Pyrrolidinones/administration & dosage ; Quinolines/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Autorzy :
Ji J; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Liu Z; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Kuang P; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Dong T; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Chen X; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Li J; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Zhang C; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Liu J; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Zhang L; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Shen K; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Liu T; Department of Hematology, Institute of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Dec 15; Vol. 149 (12), pp. 2075-2082. Date of Electronic Publication: 2021 Aug 25.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Lymphoma, Non-Hodgkin/*therapy
Neoplasm Recurrence, Local/*therapy
Transplantation Conditioning/*methods
Adolescent ; Adult ; Aged ; Aminopyridines/administration & dosage ; Aminopyridines/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzamides/administration & dosage ; Benzamides/adverse effects ; Busulfan/administration & dosage ; Busulfan/adverse effects ; Cladribine/administration & dosage ; Cladribine/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Non-Hodgkin/mortality ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Progression-Free Survival ; Transplantation Conditioning/adverse effects ; Transplantation, Autologous ; Young Adult
Czasopismo naukowe
Tytuł :
FV-429 enhances the efficacy of paclitaxel in NSCLC by reprogramming HIF-1α-modulated FattyAcid metabolism.
Autorzy :
Guo Y; School of Biopharmacy, China Pharmaceutical University, #639 Longmian Avenue, Nanjing, 211198, People's Republic of China.
Yang L; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China.
Guo W; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China.
Wei L; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China. Electronic address: .
Zhou Y; State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, #24 Tongjiaxiang, Nanjing, 210009, People's Republic of China. Electronic address: .
Pokaż więcej
Źródło :
Chemico-biological interactions [Chem Biol Interact] 2021 Dec 01; Vol. 350, pp. 109702. Date of Electronic Publication: 2021 Oct 12.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*metabolism
Flavonoids/*administration & dosage
Hypoxia-Inducible Factor 1, alpha Subunit/*metabolism
Lung Neoplasms/*drug therapy
Lung Neoplasms/*metabolism
Paclitaxel/*administration & dosage
A549 Cells ; Active Transport, Cell Nucleus/drug effects ; Animals ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Agents, Phytogenic/toxicity ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Drug Synergism ; Fatty Acids/metabolism ; Flavonoids/toxicity ; G2 Phase Cell Cycle Checkpoints/drug effects ; Humans ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Paclitaxel/toxicity ; Tumor Hypoxia/drug effects ; Wnt Signaling Pathway/drug effects ; Xenograft Model Antitumor Assays ; beta Catenin/metabolism
Czasopismo naukowe
Tytuł :
Safety and efficacy of different doses of anthracyclines combined with arsenic trioxide and all-trans retinoic acid in the treatment of de novo acute promyelocytic leukemia.
Autorzy :
Wu Y; Soochow Hopes Hematology Hospital, Suzhou, People's Republic of China.; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Ke P; Shenzhen People's Hospital, Shenzhen, People's Republic of China.; The Second Clinical Medical College of Jinan University, Guangzhou, People's Republic of China.
Zhou H; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Wu D; Soochow Hopes Hematology Hospital, Suzhou, People's Republic of China.; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Chen S; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Qiu H; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Han Y; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Li C; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Ma X; Soochow Hopes Hematology Hospital, Suzhou, People's Republic of China.; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Sun A; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Tang X; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Hu X; Soochow Hopes Hematology Hospital, Suzhou, People's Republic of China.; The First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China.; Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People's Republic of China.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 271-276.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Promyelocytic, Acute/*drug therapy
Adolescent ; Adult ; Aged ; Anthracyclines/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Arsenic Trioxide/administration & dosage ; Biomarkers, Tumor ; Bone Marrow/pathology ; Disease Management ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Leukemia, Promyelocytic, Acute/diagnosis ; Leukemia, Promyelocytic, Acute/mortality ; Male ; Middle Aged ; Prognosis ; Treatment Outcome ; Tretinoin/administration & dosage ; Young Adult
Czasopismo naukowe
Tytuł :
Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Autorzy :
Janssen QP; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
van Dam JL; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Kivits IG; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Besselink MG; Department of Surgery, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.
van Eijck CHJ; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Homs MYV; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Nuyttens JJME; Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Qi H; Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
van Santvoort HJ; Department of Surgery, Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Nieuwegein, The Netherlands.
Wei AC; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
de Wilde RF; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Wilmink JW; Department of Medical Oncology, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.
van Tienhoven G; Department of Radiation Oncology, Cancer Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.
Groot Koerkamp B; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. .
Pokaż więcej
Źródło :
Annals of surgical oncology [Ann Surg Oncol] 2021 Dec; Vol. 28 (13), pp. 8297-8308. Date of Electronic Publication: 2021 Jun 17.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Pancreatic Neoplasms*/drug therapy
Fluorouracil/therapeutic use ; Humans ; Irinotecan ; Leucovorin/therapeutic use ; Neoadjuvant Therapy ; Oxaliplatin ; Prospective Studies
Czasopismo naukowe
Tytuł :
Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial.
Autorzy :
Chen X; Department of Medical Oncology Center, Bayi Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
Qin S; Department of Medical Oncology Center, Bayi Affiliated Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
Gu S; Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China.
Ren Z; Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Chen Z; Department of Medical Oncology, The Second Hospital of Anhui Medical University, Hefei, China.
Xiong J; Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Liu Y; Department of Medical Oncology, Henan Cancer Hospital, Zhengzhou, China.
Meng Z; Minimally Invasive Therapy Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhang X; Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Wang L; Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Zhang X; Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Zou J; Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Dec 01; Vol. 149 (11), pp. 1944-1954. Date of Electronic Publication: 2021 Sep 08.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antibodies, Monoclonal, Humanized/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biliary Tract Neoplasms/*drug therapy
Oxaliplatin/*therapeutic use
Adult ; Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Biliary Tract Neoplasms/pathology ; China ; Female ; Humans ; Male ; Middle Aged ; Oxaliplatin/adverse effects ; Progression-Free Survival ; Safety ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis.
Autorzy :
Edahiro T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Kawase T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Nagoshi H; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Fujino K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Toishigawa K; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Miyama T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Mino T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Yoshida T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Morioka T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Hirata Y; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Noma M; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Fujii T; Division of Transfusion Medicine, Hiroshima University Hospital, Hiroshima, Japan.
Nishizawa M; Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Fukushima N; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Ichinohe T; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.; Next Generation Development of Genome and Cellular Therapy Program, Research Institute for Radiation Biology and Medicine (RIRBM), Hiroshima University, Hiroshima, Japan.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 186-198.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Hematopoietic Stem Cell Transplantation*/methods
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/methods
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hematologic Neoplasms/*therapy
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Busulfan/administration & dosage ; Combined Modality Therapy ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Hematologic Neoplasms/diagnosis ; Hematologic Neoplasms/mortality ; Humans ; Male ; Melphalan/administration & dosage ; Middle Aged ; Myeloablative Agonists/administration & dosage ; Recurrence ; Remission Induction ; Retrospective Studies ; Survival Analysis ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/analogs & derivatives ; Young Adult
Czasopismo naukowe
Tytuł :
Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
Autorzy :
Pan Q; Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Li J; Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 577-587.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cladribine/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cladribine/adverse effects ; Humans ; Induction Chemotherapy ; Leukemia, Myeloid, Acute/diagnosis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma.
Autorzy :
Dickinson M; Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
Briones J; Hematology Department, Hospital de la Santa Creu i Sant Pau, Sant Pau, Spain.; Jose Carreras Leukemia Research Institutes, Autonomous University of Barcelona, Barcelona, Spain.
Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
González-Barca E; Department of Hematology, Institut Català d'Oncologia, Hospital duran i Reynals, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, L'Hospitalet de LLobregat, Barcelona, Spain.
Ghosh N; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC.
Cordoba R; Department of Hematology, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.
Rutherford SC; Meyer Cancer Center, Division of Hematology and Medical Oncology, Weill Department of Medicine, NewYork-Presbyterian Hospital, Weill Cornell Medicine, New York, NY.
Bournazou E; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Labriola-Tompkins E; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Franjkovic I; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
Chesne E; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Brouwer-Visser J; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Lechner K; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
Brennan B; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Nüesch E; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
DeMario M; Roche Innovation Center New York, Roche Pharma Research and Early Development, New York, NY.
Rüttinger D; Roche Innovation Center Munich, Roche Pharma Research and Early Development, Penzberg, Germany.
Kornacker M; Roche Innovation Center Basel, Roche Pharma Research and Early Development, Basel, Switzerland.
Hutchings M; Department of Hematology and.; Phase 1 Unit, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Pokaż więcej
Źródło :
Blood advances [Blood Adv] 2021 Nov 23; Vol. 5 (22), pp. 4762-4770.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Bridged Bicyclo Compounds, Heterocyclic ; Humans ; Neoplasm Recurrence, Local/drug therapy ; Rituximab/therapeutic use ; Sulfonamides
Czasopismo naukowe
Tytuł :
Use and results of systemic treatments for de novo and recurrent metastatic breast cancer: a population-based cohort study.
Autorzy :
Lao C; Medical Research Centre, The University of Waikato, Hamilton, New Zealand.
Kuper-Hommel M; Medical Oncology, Waikato District Health Board, Hamilton, New Zealand.
Campbell I; School of Medicine, The University of Auckland, Auckland, New Zealand; General Surgery, Waikato District Health Board, Hamilton, New Zealand.
Elwood M; School of Population Health, The University of Auckland, Auckland, New Zealand.
Lawrenson R; Medical Research Centre, The University of Waikato, Hamilton, New Zealand; Strategy and Funding, Waikato District Health Board, Hamilton, New Zealand.
Pokaż więcej
Źródło :
The New Zealand medical journal [N Z Med J] 2021 Nov 12; Vol. 134 (1545), pp. 47-59. Date of Electronic Publication: 2021 Nov 12.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*
Breast Neoplasms/*therapy
Neoplasm Recurrence, Local/*therapy
Aged ; Aged, 80 and over ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Middle Aged ; New Zealand
Czasopismo naukowe
Tytuł :
DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?
Autorzy :
Major A; Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois.
Smith SM; Section of Hematology/Oncology, The University of Chicago, Chicago, Illinois.
Pokaż więcej
Źródło :
Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2021 Nov; Vol. 19 (11), pp. 698-709.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Lymphoma, Large B-Cell, Diffuse*/drug therapy
Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Etoposide/therapeutic use ; Humans ; Prednisone/therapeutic use ; Rituximab/therapeutic use ; Treatment Outcome ; Vincristine/therapeutic use
SCR Protocol :
EPOCH protocol
Czasopismo naukowe
Tytuł :
Clinical Impact of a Shortened Infusion Duration of Ramucirumab in Japanese Patients -A Model-Based Approach.
Autorzy :
Mitani S
Chen Y
Inoue K
Mori J
Gao L
Long A
Wakabayashi S
Pokaż więcej
Źródło :
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2021 Nov; Vol. 48 (11), pp. 1381-1387.
Typ publikacji :
Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized*
Antineoplastic Combined Chemotherapy Protocols*
Aged ; Clinical Trials as Topic ; Humans ; Japan ; Time Factors
Czasopismo naukowe
Tytuł :
A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.
Autorzy :
Sasaki M; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan. .; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. .
Ueno H; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Mitsunaga S; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Ohba A; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Hosoi H; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Kobayashi S; Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Ueno M; Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Terazawa T; Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Osaka, Japan.
Goto M; Cancer Chemotherapy Center, Osaka Medical College Hospital, Takatsuki, Osaka, Japan.
Inoue D; Department of Gastroenterology and Hepatology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo, Japan.
Namiki S; Department of Gastroenterology and Hepatology, Tokyo Metropolitan Tama Medical Center, Fuchu, Tokyo, Japan.
Sakamoto Y; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Kondo S; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Morizane C; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Ikeda M; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Okusaka T; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2021 Nov; Vol. 26 (11), pp. 2065-2072. Date of Electronic Publication: 2021 Aug 08.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Pancreatic Neoplasms*/drug therapy
Filgrastim ; Fluorouracil/adverse effects ; Humans ; Irinotecan/therapeutic use ; Japan ; Leucovorin ; Oxaliplatin/therapeutic use ; Polyethylene Glycols
Czasopismo naukowe
Tytuł :
Women are predisposed to early dose-limiting toxicities during adjuvant CAPOX for colorectal cancer.
Autorzy :
Nozawa H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kawai K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sasaki K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Murono K; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Emoto S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yokoyama Y; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Abe S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kishikawa J; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Nagai Y; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Sonoda H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Anzai H; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ozawa T; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Ishihara S; Department of Surgical Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Pokaż więcej
Źródło :
International journal of clinical practice [Int J Clin Pract] 2021 Nov; Vol. 75 (11), pp. e14863. Date of Electronic Publication: 2021 Sep 18.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*
Colorectal Neoplasms*/drug therapy
Capecitabine/therapeutic use ; Chemotherapy, Adjuvant ; Female ; Fluorouracil/therapeutic use ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Oxaliplatin/therapeutic use
Czasopismo naukowe
Tytuł :
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Autorzy :
Nakazato T; Department of Hematology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawanishicho, Kanagawa-ku, Yokohama, 221-0855, Japan. .
Hagihara M; Department of Hematology, Eiju General Hospital, Tokyo, Japan.
Sahara N; Department of Hematology, Kanto Rosai Hospital, Kawasaki, Japan.
Tamai Y; Division of Hematology, Shonan Kamakura General Hospital, Kamakura, Japan.
Ishii R; Division of Hematology, Japan Community Health Care Organization Sagamino Hospital, Sagamihara, Japan.
Tamaki S; Department of Hematology, Ise Red Cross Hospital, Ise, Japan.
Wake A; Department of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Tajika K; Department of Hematology, Yokohama-Minami Kyosai Hospital, Yokohama, Japan.
Sakai R; Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
Kobayashi T; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Hua J; Department of Hematology, Eiju General Hospital, Tokyo, Japan.
Inoue M; Department of Hematology, Eiju General Hospital, Tokyo, Japan.
Aisa Y; Department of Hematology, Yokohama Municipal Citizen's Hospital, 1-1 Mitsuzawanishicho, Kanagawa-ku, Yokohama, 221-0855, Japan.
Fujisawa S; Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
Miyazaki K; Department of Transfusion and Cell Transplantation, Kitasato University School of Medicine, Sagamihara, Japan.
Irie S; Department of Internal Medicine, Niigata Rosai Hospital, Niigata, Japan.
Tanaka E; Division of Internal Medicine, Hayama Heart Center, Hayama, Kanagawa, Japan.
Higashihara M; Department of Hematology, Kitasato University School of Medicine, Sagamihara, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Nov; Vol. 100 (11), pp. 2745-2754. Date of Electronic Publication: 2021 Jul 31.
Typ publikacji :
Clinical Trial, Phase II; Journal Article
MeSH Terms :
Frail Elderly*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bortezomib/administration & dosage ; Bortezomib/adverse effects ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Female ; Hematologic Diseases/chemically induced ; Humans ; Hyponatremia/chemically induced ; Japan ; Kaplan-Meier Estimate ; Male ; Peripheral Nervous System Diseases/chemically induced ; Precision Medicine ; Progression-Free Survival ; Prospective Studies ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies